記住我
REVIEW ARTICLE
Year : 2022 | Volume
: 12
| Issue : 6 | Page : 233-242
Prodigiosin from Serratia: Synthesis and potential applications
Sami Mnif1, Marwa Jardak1, Brahim Bouizgarne2, Sami Aifa1
1 Laboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, University of Sfax, PO box 1177, Road Sidi Mansour km 6, 3018 Sfax, Tunisia
2 Laboratory "Plant Biotechnology", Department of Biology, Faculty of Sciences, University Ibn Zohr, B.P 8106, 80000 Agadir, Morocco
Correspondence Address:
Sami Mnif
Laboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, University of Sfax, PO box 1177, Road Sidi Mansour km 6, 3018 Sfax
Tunisia
Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2221-1691.345515
Prodigiosin is a red pigment with a pyrrolylpyrromethane skeleton. It is mainly produced by bacterial strains belonging to the Serratia genus, but also by some other genera, including Streptomyces and Vibrio. Within the genus Serratia, the pigment is generally produced as a virulence factor. However, it also has many important beneficial biological activities such as immunosuppressive and anti- proliferative activities. Moreover, the pigment has many industrial applications in textile and cosmetics. In this mini-review, we discuss the genetic and molecular mechanisms supporting prodigiosin synthesis and production from the Serratia genus, as well as its potential applications.
Keywords: Prodigiosin; Serratia; Synthesis; Metabolites; Biological activities; Applications; Antimicrobial; Anti-proliferative
Among natural products, secondary metabolites are obtained from two main sources: plants, and microorganisms. As secondary metabolites, they are generally classified as low molecular weight products that have generally little or no proven function in cell vital metabolisms. Secondary metabolites produced and secreted by microorganisms are of great interest. Certainly, these metabolites have numerous pharmaceutical properties, which will benefit human health and nutrition as well as add economical value. Biopigments, produced either by microorganisms or plants, are among the most abundant classes of secondary metabolites[1]. As a result of their stability and year-round availability, biopigments from microorganisms have been preferred over those from plants. Conversely, plant biopigments suffer from many disadvantages, such as being unstable to heat and light. Prodigiosin is one of these microbial biopigments[1]. Prodigiosin is considered an important molecule since it has been applied in various fields and represents a promising area of research. Prodigiosin belongs to a family of natural red pigments (prodiginins) of low molecular weight (323.4 Daltons) that appear only in the later stages of bacterial growth called idiophase. Prodigiosin (C20H25N3O) is produced by many strains of Serratia spp. It is associated with extracellular vesicles or found in intracellular granules[1].
Prodigiosin is a member of the prodiginines[2]. It is a hydrophobic compound with a Log POW of 5.16[3] and has been reported as responsible for cell surface hydrophobicity in various Serratia strains[4]. The prodigiosin group belongs to the tripyrrole family, which contains a 4-methoxy, 2-2 bipyrrole ring. Its biosynthesis is a two-step process in which the mono- and bipyrrole precursors are first synthesized as two distinct units and then combined to form the final product, prodigiosin [Figure 1][5]. In this review, we investigate the exact mechanism of prodigiosin production, including structural pathways, molecular regulation in Serratia strains, and potent biological activities of this versatile compound. Moreover, the recent advances in large-scale production of prodigiosin are also discussed.
2. Prodigiosin-producing microorganismsProdigiosin has long been a subject of research interest because of its many potential beneficial properties. It belongs to the family of prodiginins [Figure 2]. This metabolite is secreted by several microorganisms such as Vibrio ruber[6], Hahella chejuensis[7], Zooshikella sp.[8], Streptomyces coelicolor[9], Streptomyces griseoviridis[ 10], Serratia nematodiphila[11], Serratia rubidaea[12] and Serratia marcescens (S. marcescens)[13]. The most widely known source is S. marcescens[14].
3. Prodigiosin synthesisAs shown in [Figure 3], the biosynthesis of prodigiosin results from the condensation of two key intermediates, 2-methyl-3-n-amylpyrrole (MAP) and 4-methoxy-2-2’-bipyrrole-5-carbaldehyde (MBC)[15].
Figure 3: Final step of prodigiosin biosynthesis. MAP: 2-methyl-3-n-amylpyrrole, MBC: 4-methoxy-2-2'-bipyrrole-5-carbaldehyde, ATP: adenosine triphosphate.3.1. Biosynthesis of MAP fragment
The original precursor to this pyrrole is oct-2-enal, which can be obtained by fatty acid transformations. When oct-2-enal reacts with pyruvate in the presence of thiamine pyrophosphate, it produces CO2 and 3-acetyloctanal [Figure 4]. In the presence of amino acid, an aminotransferase produces the cyclic imine H2MAP. This imine is eventually oxidized by a flavin (flavin adenine dinucleotide) to MAP[16][Figure 4].
Figure 4: Biosynthesis of MAP fragment. H2MAP: dihydroMAP, MAP: 2 methyl-3-n-amylpyrrole, TPP: thiamine pyrophosphate, PLP: pyridoxal 5′-phosphate, FAD/FADH2: flavin adenine dinucleotide.3.2. Biosynthesis of MBC fragment
The first step in the synthesis of MBC is the conversion of proline to a pyrrole via a thioester intermediate. ATP activates and transfers it to a thiol of a PCP transport protein (peptidyl carrier protein) [Figure 5]. This compound undergoes double oxidation with flavin adenine dinucleotide, to lead to the pyrrole core. The pyrrole moiety is transferred to an active site of cysteine and then to a malonyl group. The latter has been previously decarboxylated and is derived from the malonyl-CoA complex. Thus, the pyrrolyl-P- ketothioester is formed. Condensation of a serine gives 4’-hydroxy- 2,2’-bipyrrole-5-methanol by transamination. The primary alcohol in 4’-hydroxy-2,2’-bipyrrole-5-methanol is oxidized to carboxaldehyde. Methylation occurs with a methyltransferase from S-adenosylmethionine (AdoMet) to provide the MBC fragment[16][Figure 5].
Figure 5: Biosynthesis of MBC fragment. PCP: peptidyl carrier protein, HBM: 4 hydroxy-2-2-bipyrrol-5-methanol, NAD(P): nicotinamide adenine dinucleotide (phosphate), FMN: flavin mononucleotide, AdoMeth: S-adenosylmethionine, MBC: 4-methoxy-2-2'-bipyrrole-5-carbaldehyde; PLP: pyridoxal phosphate. 4. Genetic organization of the group of biosynthetic genes of prodigiosin The pig cluster comprises 14 genes and is 20 960 bp in size. These genes are arranged in the order of pigA, pigB, pigC, pigD, pigE, pigF, pigG, pigH, pig1, pigJ, pigK, pigL, pigM and pigN [Figure 6][16]. The function of each corresponding protein is listed in [Table 1]. The green arrows indicate the genes involved in the biosynthesis of the monopyrrole fragment, MAP, while the blue arrows represent the genes involved in the synthesis of the bipyrrole group, MBC. The red arrow is the gene that encodes for the terminal condensation enzyme, pigC. Transcriptional regulators of prodigiosin expression are indicated by yellow arrows [Figure 6]. PigG and pigA are involved in the early steps of MBC biosynthesis[17]. PigJ and pigH are involved in the biosynthesis of MBC[16]. All genes encoded for known proteins except pigK for which no assigned function is known[16],[18]. Indeed, in Serratia, deletion of pigK has no effects on prodigiosin production. It was suggested that pigK may have a role in assisting the folding of one or more of the Pig enzymes involved in the later stages of MBC biosynthesis[18].
Figure 6: Biosynthetic genes for prodigiosin biosynthesis. The blue arrows represent the genes involved in the synthesis of the bipyrrole group, MBC; the green arrows indicate the genes involved in the biosynthesis of the monopyrrole fragment, MAP; the red arrow is the gene that encodes for the terminal condensation enzyme and the yellow arrows indicate transcriptional regulators of prodigiosin expression. 5. Control of prodigiosin production by quorum sensing Generally, prodigiosin production is controlled by the quorum- sensing regulatory system, which controls biofilm formation and virulence factor production in Serratia and other bacterial genera.
In Serratia sp. ATCC 39006, prodigiosin production is regulated by the SmaI/SmaR quorum-sensing system and its cognate N-acylhomoserine lactones, N-butanoyl-L-homoserine lactone (C4-HSL), and N-hexanoyl-L-homoserine lactone (C6-HSL), the former being the more abundant molecule[19]. SmaR is a repressor of Pig when the levels of N-acyl-L-homoserine lactones, produced by SmaI, are low[17]. At low cell density, transcription of the pig cluster is repressed by SmaR, whereas at high cell density, binding of C4-HSL/C 6-HSL to SmaR derepresses transcription. In addition, the production of prodigiosin also depends on quorum sensing system within the strain of S. marcescens SS-1. The regulation of prodigiosin production is coordinated by two LuxI/LuxR homologues which are SpnI/SpnR. Autoinducers involved in this regulation were identified as 3-oxo-C6HSL, C6-HSL, C7-HSL, and C8-HSL[20]. More recent investigations showed that a PigP has a significant regulatory role in Serratia sp. ATCC 39006 and acts by binding to DNA (transcriptional regulator). It also seems that environmental conditions mainly phosphate availability could regulate prodigiosin synthesis[21].
6. Medical, pharmaceutical, and industrial applications of prodigiosinProdigiosin has recently received great attention for its wide range of biological activities, including antimalarial, antifungal, and antibiotic activities. Moreover, it also has anti-cancer, and anti- metastatic properties and is best known for its ability to trigger apoptosis in cancer cells. However, the molecular mechanisms responsible for these abilities are not fully understood[22]. Some of these activities and applications are detailed below.
6.1. Antimicrobial activity
6.1.1. Antibacterial activity
The antibacterial activity of prodigiosin is higher against Gram- positive bacteria such as Staphylococcus aureus, Staphylococcus saprophyticus, Bacillus subtilis, Enterococcus avium, and Streptococcus pyogenes compared to Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, and Klebsiella aerogenes[22],[23]. Prodigiosin has also been shown to be effective against Borrelia burgdorferi, the causative agent of Lyme disease[24]. Hage-Hülsmann et al. reported the minimum inhibitory concentration (MIC) value of prodigiosin against Corynebacterium glutamicum of 2.56 μg/mL which was improved in the presence of N-myristoyltyrosine to 0.005 μg/mL[25]. It has been demonstrated that the antibacterial activity of prodigiosin arises from its ability to cross the outer membrane and inhibit target enzymes such as DNA gyrase and topoisomerase IV, thus blocking cell growth by generating reactive oxygen species (ROS) that damage biological molecules[16]. Furthermore, other studies by Kimyon et al.[26] showed that the mechanism of action of prodigiosin is a nonspecific mechanism of procaryotes that involves RNA and DNA fragmentation, ROS generation, and expression of protein with caspase-like substrate specificity in bacterial cells. and activation of the programmed cell death[16],[26].
Moreover, prodigiosin can be used in certain textile applications, particularly in hospitals to reduce nosocomial infections. A recent study showed that this attractive color pigment, which was extracted from Serratia rubidaea RAM-Alex and used for dyeing various textile fabrics, had both good dyeing performance and antibacterial activity against Escherichia coli ATCC8739 and Staphylococcus aureus ATCC25923 strains[27].
MIC and minimum bactericidal concentration values of prodigiosin against some Gram-positive and Gram-negative bacteria are represented in [Table 2].
Table 2: Antibacterial activities of prodigiosin against some Gram-positive and Gram-negative bacteria.6.1.2. Antifungal activity
The prodigiosin pigment is also renowned for its antifungal activity against several fungal strains. Suryawanshi et al. demonstrated that prodigiosin inhibited the growth of fungal strains Fusarium oxysporum, Aspergillus flavus, and Penicillium notatum with MICs of 8, 10, and 21 μg/mL, respectively[28]. Other studies have demonstrated the antifungal activity of prodigiosin against several fungal strains including Epidermophyton floccosum (MIC = 41.5 μg/mL), Trichophyton spp. (MIC = 5.8-13.5 μg/mL), Microsporum spp. (MIC = 2.0-5.6 μg/mL)[29], Botrytis cinerea (MIC = 100 μg/mL)[30] and Didymella applanata (IC50 = 0.8 μg/mL)[31]. Recently, inhibition of the human fungal pathogen Mucor irregularis was reported by Hazarika et al. where prodigiosin, produced by the S. marcescens D1, induced increasing permeability in fungal cell membrane that helps the bacterium to invade fungal hyphae[32].
6.2. Antimalarial activity
Prodigiosin is characterized by its antimalarial activity, which was firstly studied by Castro in 1967. Papireddy et al. studied the antimalarial activity of the pigments prodigiosin and undecylprodigiosin which showed interesting activities against Plasmodium falciparum (P. falciparum) with IC50 of 8 and 7.7 nM, respectively[33]. P. falciparum was also sensitive to the action of metacycloprodigiosin with an IC50 of 12 nM[34]. Newly synthesized prodigiosin derivatives exhibited asexual blood-stage antiplasmodial activity at low nanomolar concentration against a panel of P. falciparum parasites[35].
6.3. Antiparasitic activity
Prodigiosin pigment is also recognized for its antiparasitic activities. The effects of prodigiosin against several parasites Entamoeba histolytica, Giardia lamblia, Naegleria fowleri, Acanthamoeba castellanii, Balamuthia mandrillaris (trophozoites), Balamuthia mandrillaris (cysts), Cryptosporidium parvum, Schistosoma mansoni, and Trypanosoma brucei were observed with IC50 values of 0.7, 3.8, 6.4, 2.2, 4, 3.8, 0.09, 1 and 0.03 μM, respectively[36]. Another study reported by Rahul et al. showed that prodigiosin, produced by Serratia nematodiphila, inhibited the growth of Trypanosoma brucei gambiense and P. falciparum, with IC50 values of 0.158 and 1.1 μg/mL, respectively[37]. Moreover, prodigiosin PG 3, produced by S. marcescens 2170, exhibited strong antiparasitic activity against Trypanosoma cruzi (souche CL, clone B5) with an IC50 of 0.6 μM in comparison with the current drug benznidazole with an IC50 of 18.9 μM[38]. Additionally, prodigiosin treatment led to severe membrane damage in Trypanosoma cruzi epimastigotes, accompanied by a change in parasite cell height and the surface roughness[38].
6.4. Insecticidal activity
Several studies demonstrated the efficacy of prodigiosin as an insecticidal pigment[39],[40],[41]. Sree et al. reported insecticidal activity and confirmed the efficacy of prodigiosin to kill various household pests. Indeed, total death of Periplaneta americana (Cockroaches) and Solenopsis geminata (tropical ants) was observed after treatment with prodigiosin, while 71%-85% mortality was observed against Dorymyrmex insanus (pyramid ants) and Isoptera (termites)[42].
6.5. Antioxidant activity
The antioxidant activity of prodigiosin was evaluated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2’-azino- bis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) assays. The IC50 values recorded for DPPH and ABTS assays were 235 and 115 μg/mL, respectively in comparison to alpha-tocopherol with IC50 values of 24.3 and 12.7, respectively[43]. On the other hand, Arivizhivendhan et al. studied the antioxidant potential of prodigiosin, which was examined by DPPH and ABTS radical scavenging assays. Antioxidant activity was assessed via UV-visible, electron spin resonance, cyclic voltammetry, and excitation-emission spectra. The DPPH and ABTS radicals were completely scavenged by prodigiosin at the concentration of 10 mg/L[44].
6.6. Anticancer activity
Cancer is a global scourge. According to the World Health Organization, there were 19 million newly diagnosed cancer cases and 10 million cancer-related deaths globally in 2020. Cancer tends to be the leading cause of death in Western countries. It is a serious disease that can occur in any organ and at any age. Due to its severity, cancer causes profound anxiety and fear in most people. In view of this awareness, it is, therefore, necessary to find new anti- tumor agents that ideally have specific targets in the affected cells. Boger et al. demonstrated the anticancer effects of prodiginins[45]. Their results showed that prodigiosin has a significant in vitro cytotoxic effect on leukemic embryonic stem cells (IC50 = 3.7 × 10-4 μg/mL). Subsequent studies have demonstrated the effect of prodiginins on human leukemia cells (IC50 = 0.11 pM)[46], colon cancer (IC50 = 0.27 μM)[47], breast cancer (IC50 = 2.1 μM)[48], and hepatocellular carcinoma (IC50 = 0.27-0.59 μM)[49]. Many researches also focused on other tumor cell lines such as gastric cancer[50], hematopoietic cancer[51], and lung cancer[52]. Although the molecular targets of prodigiosin are not clearly defined, prodigiosin can target various signaling pathways that induce double-stranded DNA breaks and/or neutralize pH gradients, leading to changes in the cell cycle[53]. Another possible mechanism of prodigiosin action against cancer cells is the inhibition of protein phosphatase activity[54]. In 2016, Wang et al. reported that prodigiosin and its analogue obatoclax block Wnt signaling at nanomolar concentrations by preventing the Dishevelled phosphorylation. Cyclin D is an established target of Wnt signaling, and elevated cyclin D levels are a characteristic of advanced breast cancer. In a Wnt-driven murine transgenic model of breast cancer, prodigiosin decreased the levels of cyclin D and inhibited tumor growth[55]. In another study, it has been demonstrated that prodigiosin could induce apoptosis in HeLa cells. Apoptosis may be associated with the upregulation of Bax and caspase 3, the concomitant downregulation of Bcl-2 levels, and the activation of the extrinsic apoptotic signaling pathway[56]. These results provide a rationale for the introduction of prodigiosin analogues in advanced breast cancer clinical trials[55].
6.7. Anti-inflammatory activity
Cyclooxygenases (COX) or prostaglandin-endoperoxide synthases are the key enzymes in the synthesis of prostaglandins, the main mediator of inflammation, pain, and increased body temperature (hyperpyrexia). The body produces two forms of COX protein, COX1, and COX2. COX1 is involved in pain, blood clots, and stomach protection[57], whereas COX-2 is involved in pain by inflammation and plays a major role in prostaglandin biosynthesis in inflammatory cells and the central nervous systems[58]. The in silico anti-inflammatory activity of prodigiosin has been proven. Using molecular docking, the prodigiosin ligand revealed the highest fitness, score in comparison with the standard drug rofecoxib, suggesting that it may be an effective COX-2 inhibitor[59].
7. Large-scale production of prodigiosinSeveral biological activities have been reported for prodigiosin such as antibacterial, antifungal, antiparasitic, insecticidal, anticancer, antioxidant, and anti-inflammatory activities. This product is gaining more and more attention for its wide application in several medical, cosmetic, environmental, and food fields. Han et al. emphasize the importance of producing this pigment at a large scale while minimizing production costs[60].
Recently, several studies have been devoted to the optimization of prodigiosin production through the optimization of culture conditions, medium composition, and fermentation methods. The composition of the medium plays a critical role in the production of prodigiosin. In some studies, researchers have found that yeast extract or peptone and sucrose are important nitrogen and carbon sources for the production of prodigiosin by the S. marcescens strain[61],[62],[63]. On the other hand, glycerol has been proven by some researchers as an important source of carbon promoting better production of prodigiosin[64].
The prodigiosin synthesis pathway requires the amino acids proline, serine, and methionine as synthesis precursors. Adding these amino acids can stimulate the synthesis of the MBC precursor and enhance the production of the prodigiosin pigment[65].
In addition, the other precursor of prodigiosin 2-octenal, which is the initiator of MAP synthesis, is obtained essentially from the oxidation of fatty acids. Subsequently, the addition of oils such as olive oil[66], sunflower oil[67], palm oil[68], and peanut powder[69] could improve the production of prodigiosin. Several studies have been devoted to the search for low-cost substrates to minimize the cost of prodigiosin production, including kitchen waste[70], squid pen powder[41], and a-chitin from shrimp shells[71].
The production yield of prodigiosin is also affected by cultural conditions such as pH, temperature[63], oxygen levels[72], agitation[73], illumination[74], and the presence of salts[75]. Large- scale production of prodigiosin is achieved through the fermentation process. All biological, physical, and chemical conditions must be present to maximize production yield. The fermentation process for prodigiosin production has been studied using liquid and solid fermentation cultures[76],[77], foam flotation method for continuous fermentation[78], and immobilized culture[79].
8. Prospects and conclusionThe synthesis of secondary metabolites by microorganisms in response to environmental stress is an important source of bioactive molecules. Indeed, secondary metabolites can serve as bioactive molecules in a variety of industries including medicine, food, or environmental fields. Biopigment prodigiosin is useful for numerous applications in a wide range of fields. The mechanism of prodigiosin synthesis is complex and involves many genes. It is regulated by quorum sensing system within the species S. marcescens and even with other microorganisms.
Studies are being conducted to lower the costs of prodigiosin production on a large scale through the use of economic media and to develop innovative downstream processing strategies for this compound. Moreover, the pharmacodynamic, pharmacokinetic and toxic information of prodigiosin in animals needs further investigation. Current works are also oriented towards the development of new prodigiosin derivatives which will certainly display more potent activity than the parent compound.
Conflict of interest statement
The authors declare that they have no competing interests.
Acknowledgments
The Tunisian ministry of higher education and scientific research is acknowledged.
Authors’ contributions
SM and MJ were responsible for writing and original draft preparation, BB and SA reviewed and edited the manuscript. All authors read and approved the final manuscript.
References
留言 (0)